Computational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors

Biochemistry

Volumn 49, Issue 19, 2010, Pages 4283-4295

  Genoni, Alessandro ^a,b   Morra, Giulia ^a   Merz Jr , Kenneth M ^b   Colombo, Giorgio ^a  

^a CNR   (Italy)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; ACTIVE SITE RESIDUES; ALLOSTERIC INHIBITOR; ANTIRETROVIRALS; BINDING POCKETS; BOUND INHIBITORS; COMPUTATIONAL ANALYSIS; COMPUTATIONAL STUDIES; DRUG RESISTANCE; DRUG TARGETS; DYNAMIC COORDINATION; ENERGETIC PROPERTIES; ENERGY NETWORKS; HIV-1 PROTEASE; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; MUTATION RATES; SIGNAL PROPAGATION; STRUCTURAL ORGANIZATION; WILD TYPES;

COORDINATION REACTIONS; DRUG THERAPY; DYNAMICS; ENZYMES; VIRUSES;

DISEASES;

INDINAVIR; NELFINAVIR; PROTEINASE;

ALLOSTERISM; ARTICLE; ATOM; ENERGY TRANSFER; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; VIRUS MUTANT; VIRUS RESISTANCE; WILD TYPE;

COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77952387383     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi100569u     Document Type: Article

References (92)

1. Katzenstein, D. (2006) Diversity, Drug Resistance, and the Epidemic of Subtype C HIV-1 in Africa J. Infect. Dis. 194, S45-S50
2. Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Jr., Feinberg, J. E., Balfour, H. H., Jr., Deyton, L. R., Chodakewitz, J. A., and Fischl, M. A. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team N. Engl. J. Med. 337, 725-733
3. Deeks, S. G., Smith, M., Holodniy, M., and Kahn, J. O. (1997) HIV-1 protease inhibitors. A review for clinicians J. Am. Med. Assoc. 277, 145-153
4. Carpeenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., Thompson, M. A., Vella, S., Yeni, P. G., and Volberding, P. A. (1997) Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel J. Am. Med. Assoc. 277, 1962-1969
5. Wlodawer, A. and Erickson, J. W. (1993) Structure-based inhibitors of HIV-1 protease Annu. Rev. Biochem. 62, 543-585
6. Debouck, C. (1992) The HIV-1 protease as a therapeutic target for AIDS AIDS Res. Hum. Retroviruses 8, 153-164
7. Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., Scolnick, E. M., and Sigal, I. S. (1988) Active human immunodeficiency virus protease is required for viral infectivity Proc. Natl. Acad. Sci. U.S.A. 85, 4686-4690
8. Peng, C., Ho, B. K., Chang, T. W., and Chang, N. T. (1989) Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity J. Virol. 63, 2550-2556
9. Frankel, A. D. and Young, J. A. T. (1998) HIV-1: Fifteen proteins and an RNA Annu. Rev. Biochem. 67, 1-25
10. Wlodawer, A. and Gustchina, A. (2000) Structural and biochemical studies of retroviral proteases Biochim. Biophys. Acta 1477, 16-34
11. Tomasselli, A. G. and Heinrikson, R. L. (2000) Targeting the HIV-protease in AIDS therapy: A current clinical perspective Biochim. Biophys. Acta 1477, 189-214
12. Hamelberg, D. and McCammon, J. A. (2005) Fast Peptidyl cis-trans Isomerization within the Flexible Gly-Rich Flaps of HIV-1 Protease J. Am. Chem. Soc. 127, 13778-13779
13. Hornak, V., Okur, A., Rizzo, R. C., and Simmerling, C. (2006) HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations Proc. Natl. Acad. Sci. U.S.A. 103, 915-920
14. Hornak, V. and Simmerling, C. (2007) Targeting structural flexibility in HIV-1 protease inhibitor binding Drug Discovery Today 12, 132-138
15. Ding, F., Layten, M., and Simmerling, C. (2008) Solution Structure of HIV-1 Protease Flaps Probed by Comparison of Molecular Dynamics Simulation Ensembles and EPR Experiments J. Am. Chem. Soc. 130, 7184-7185
16. Galiano, L., Ding, F., Veloro, A. M., Blackburn, M., Simmerling, C., and Fanucci, G. E. (2009) Drug Pressure Selected Mutations in HIV-1 Protease Alter Flap Conformations J. Am. Chem. Soc. 131, 430-431
17. Roberts, N. A., Martin, J. A., Kinchington, D., Broadhurst, A. V., Craig, J. C., Duncan, I. B., Galpin, S. A., Handa, B. K., Kay, J., Krohn, A., Lambert, R. W., Merrett, J. H., Mills, J. S., Parkes, K. E. B., Redshaw, S., Ritchie, A. J., Taylor, D. L., Thomas, G. J., and Machin, P. J. (1990) Rational design of peptide-based HIV proteinase inhibitors Science 248, 358-361
18. Dorsey, B. D., Levin, R. B., McDaniel, S. L., Vacca, J. P., Guare, J. P., Darke, P. L., Zugay, J. A., Emini, E. A., Schleif, W. A., Quintero, J. C., Lin, J. H., Chen, I.-W., Holloway, M. K., Fitzgerald, P. M. D., Axel, M. G., Ostovic, D., Anderson, P. S., and Huff, J. R. (1994) L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor J. Med. Chem. 37, 3443-3451 (Pubitemid 24334599)
19. Kaldor, S. W., Kalish, V. J., Davies, J. F., II, Shetty, B. V., Fritz, J. E., Appelt, K., Burgess, J. A., Campanale, K. M., Chirgadze, N. Y., Clawson, D. K., Dressman, B. A., Hatch, S. D., Khalil, D. A., Kosa, M. B., Lubbehusen, P. P., Muesing, M. A., Patick, A. K., Reich, S. H., Su, K. S., and Tatlock, J. H. (1997) Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease J. Med. Chem. 40, 3979-3985
20. Kempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., Kong, X. P., Wideburg, N. E., Saldivar, A., Ruiz, L., Kati, W. M., Sham, H. L., Robins, T., Stewart, K. D., Hsu, A., Plattner, J. J., Leonard, J. M., and Norbeck, D. W. (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans Proc. Natl. Acad. Sci. U.S.A. 92, 2484-2488
21. Lee, T. Y., Le, V.-D., Lim, D. Y., Lin, Y.-C., Morris, G. M., Wong, A. L., Olson, A. J., Elder, J. H., and Wong, C. H. (1999) Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants J. Am. Chem. Soc. 121, 1145-1155
22. Li, M., Morris, G. M., Lee, T., Laco, G. S., Wong, C. H., Olson, A. J., Elder, J. H., Wlodawer, A., and Gustchina, A. (2000) Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease Proteins 38, 29-40
23. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. A. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 374, 569-571
24. Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Shipper, P. J., Mo, H.-M., Markowitz, M., Chernyavskiy, T., Niu, P., Lyons, N., Hsu, A., Granneman, G. R., Ho, D. D., Boucher, C. A. B., Leonard, J. M., Norbeck, D. W., and Kempf, D. J. (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir Nat. Med. 2, 760-766
25. Erickson, J. W. and Burt, S. K. (1996) Structural mechanisms of HIV drug resistance Annu. Rev. Pharmacol. Toxicol. 36, 545-571
26. Wlodawer, A. and Vonrasek, J. (1998) Inhibitors of HIV-1 protease: A major success of structure-assisted drug design Annu. Rev. Biophys. Biomol. Struct. 27, 249-284
27. Dunn, B. M. (2002) Anatomy and pathology of HIV-1 peptidase Essays Biochem. 38, 113-127
28. Clemente, J. C., Robbins, A., Gaña, P., Paleo, M. R., Correa, J. F., Villaverde, M. C., Sardina, F. J., Govindasamy, L., Agbandje-McKenna, M., McKenna, R., Dunn, B. M., and Sussman, F. (2008) Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation J. Med. Chem. 51, 852-860
29. Bannwarth, L., Rose, T., Dufau, L., Vaderesse, R., Dumond, J., Jamart-Grégoire, B., Pannecouque, C., De Clercq, E., and Reboud-Ravaux, M. (2009) Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases Biochemistry 48, 379-387
30. Ala, P. J., Huston, E. E., Klabe, R. M., Jadhav, P. K., Lam, P. Y. S., and Chang, C.-H. (1998) Counteracting HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities Biochemistry 37, 15042-15049
31. Luque, I., Todd, M. J., Gómez, J., Semo, N., and Freire, E. (1998) Molecular basis of resistance to HIV-1 protease inhibition: A plausible hypothesis Biochemistry 37, 5791-5797
32. Rose, R. B., Craik, C. S., and Stroud, R. M. (1998) Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations Biochemistry 37, 2607-2621
33. Velázquez-Campoy, A., Todd, M. J., and Freire, E. (2000) HIV-1 protease inhibitors: Enthalpic versus entropic optimization of the binding affinity Biochemistry 39, 2201-2207
34. Todd, M. J., Luque, I., Velázquez-Campoy, A., and Freire, E. (2000) Thermodynamic basis of resistance to HIV-1 protease inhibition: Calorimetric analysis of the V82F/I84V active site resistant mutant Biochemistry 39, 11876-11883
35. Velázquez-Campoy, A., Luque, I., Todd, M. J., Milutinovich, M., Kiso, Y., and Freire, E. (2000) Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor Protein Sci. 9, 1801-1809
36. Wang, W. and Kollman, P. A. (2001) Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance Proc. Natl. Acad. Sci. U.S.A. 98, 14937-14942
37. Clemente, J. C., Hemrajani, R., Blum, L. E., Goodenow, M. M., and Dunn, B. M. (2003) Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N Biochemistry 42, 15029-15035
38. Clemente, J. C., Moose, R. E., Hemrajani, R., Whitfors, L. R. S., Govinasamy, L., Reutzel, R., McKenna, R., Agbandje-McKenna, M., Goodenow, M. M., and Dunn, B. M. (2004) Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease Biochemistry 43, 12141-12151
39. Clemente, J. C., Coman, R. M., Thiaville, M. M., Janka, L. K., Jeung, J. A., Nukoolkarn, S., Govindasamy, L., Agbandje-McKenna, M., McKenna, R., Leelamanit, W., Goodenow, M. M., and Dunn, B. M. (2006) Analysis of HIV-1 CRF-01 A/E protease inhibitor resistance: Structural determinants for maintaining sensitivity and developing resistance to atazanavir Biochemistry 45, 5468-5477
40. Sanches, M., Krauchenco, S., Martins, N. H., Gustchina, A., Wlodawer, A., and Polikarpov, I. (2007) Structural characterization of B and non-B subtypes of HIV-protease: Insights into the natural susceptibility to drug resistance development J. Mol. Biol. 369, 1029-1040
41. Foulkes-Murzycki, J. E., Scott, W. R. P., and Schiffer, C. A. (2007) Hydrophobic sliding: A possible mechanism for drug resistance in human immunodeficiency virus type 1 protease Structure 15, 225-233
42. Perryman, A. L., Lin, J. H., and McCammon, J. A. (2004) HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs Protein Sci. 13, 1108-1123
43. Perryman, A. L., Lin, J. H., and McCammon, J. A. (2004) HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs (Correction) Protein Sci. 13, 1434
44. Piana, S., Carloni, P., and Rothlisberger, U. (2002) Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations Protein Sci. 11, 2393-2402
45. Smock, R. G. and Gierasch, L. M. (2009) Sending signals dynamically Science 324, 198-203
46. Lockless, S. W. and Ranganathan, R. (1999) Evolutionarily conserved pathways of energetic connectivity in protein families Science 286, 295-299
47. Fuentes, E. J., Der, C. J., and Lee, A. L. (2004) Ligand-dependent dynamics and intramolecular signaling in a PDZ domain J. Mol. Biol. 335, 1105-1115
48. Dhulesia, A., Gsponer, J., and Vendruscolo, M. (2008) Mapping of Two Networks of Residues That Exhibit Structural and Dynamical Changes upon Binding in a PDZ Domain Protein J. Am. Chem. Soc. 130, 8931-8939
49. Ota, N. and Agard, D. A. (2005) Intramolecular signaling pathways revealed by modeling anisotropic thermal diffusion J. Mol. Biol. 351, 345-354
50. De Los Rios, P., Cecconi, F., Pretre, A., Dietler, G., Michielin, O., Piazza, F., and Juanico, B. (2005) Functional Dynamics of PDZ Binding Domains: A Normal-Modes Analysis Biophys. J. 89, 14-21
51. Kong, Y. and Karplus, M. (2009) Signaling pathways of PDZ2 domain: A molecular dynamics interaction correlation analysis Proteins 74, 145-154
52. Martin, P., Vickrey, J. F., Proteasa, G., Jimenez, Y. L., Wawrzak, Z., Winters, M. A., Merigan, T. C., and Kovari, L. C. (2005) "Wide-open" 1.3 Å structure of a multidrug-resistant HIV-1 protease as a drug target Structure 13, 1887-1895
53. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47, 1739-1749
54. Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., and Banks, J. L. (2004) Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J. Med. Chem. 47, 1750-1759
55. Case, D. A., Darden, T. A., Cheatman, T. E., III, Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Merz, K. M., Jr., Pearlman, D. A., Crowley, M., Walker, R. C., Zhang, W., Wang, B., Hayik, S., Roitberg, A., Seabra, G., Wong, K. F., Paesani, F., Wu, X., Brozell, S., Tsui, V., Gohlke, H., Yang, L., Tan, C., Mongan, J., Hornak, V., Cui, G., Beroza, P., Mathews, D. H., Schafmeister, C., Ross, W. S., and Kollman, P. A. (2006) AMBER 9, University of California, San Fancisco.
56. Wang, J., Wang, W., Kollman, P. A., and Case, D. A. (2006) Automatic atom type and bond type perception in molecular mechanical calculations J. Mol. Graphics Modell. 25, 247-260
57. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., and Case, D. A. (2004) Development and testing of a general amber force field J. Comput. Chem. 25, 1157-1174
58. Guex, N. and Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling Electrophoresis 18, 2714-2723
59. Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and Simmerling, C. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 65, 712-725
60. Jorgensen, W. L., Chandrasekar, J., Madura, J., and Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 79, 926-935
61. Darden, T., York, D., and Pedersen, L. (1993) Particle mesh Ewald: An N log(N) method for Ewald sums in large systems J. Chem. Phys. 98, 10089-10092
62. Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., and Pedersen, L. G. (1995) A smooth particle mesh Ewald method J. Chem. Phys. 103, 8577-8593
63. Crowley, M. F., Darden, T. A., Cheatman, T. E., III, and Deerfield, D. W., II (1997) Adventures in improving the scaling and accuracy of a parallel molecular dynamics program J. Supercomput. 11, 255
64. Ryckaert, J.-P., Ciccotti, G., and Berendsen, H. J. C. (1977) Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n -alkanes J. Comput. Phys. 23, 327-341
65. Pastor, R. W., Brooks, B. R., and Szabo, A. (1988) An analysis of the accuracy of Langevin and molecular dynamics algorithms Mol. Phys. 65, 1409-1419
66. Loncharich, R. J., Brooks, B. R., and Pastor, R. W. (1992) Langevin dynamics of peptides: The frictional dependence of isomerization rates of N-acetylalanyl-N-methylamide Biopolymers 32, 523-535
67. Izaguirre, J. A., Catarello, D. P., Wozniak, J. M., and Skeel, R. D. (2001) Langevin stabilization of molecular dynamics J. Chem. Phys. 114, 2090-2098
68. Chennubhotla, C. and Bahar, I. (2007) Signal Propagation in Proteins and Relation to Equilibrium Fluctuations PLoS Comput. Biol. 3, e172
69. Chennubhotla, C., Yang, Z., and Bahar, I. (2008) Coupling between global dynamics and signal transduction pathways: A mechanism of allostery for chaperonin GroEL Mol. Biosyst. 4, 287-292
70. Morra, G., Verkhivker, G., and Colombo, G. (2009) Modeling Signal Propagation Mechanisms and Ligand-Based Conformational Dynamics of the Hsp90 Molecular Chaperone Full-Length Dimer PLoS Comput. Biol. 5, e1000323
71. Colombo, G., Meli, M., Morra, G., Gabizon, R., and Gasset, M. (2009) Methionine Sulfoxides on Prion Protein Helix-3 Switch on the α-Fold Destabilization Required for Conversion PLoS One 4, e4296
72. Carnevale, V., Pontiggia, F., and Micheletti, M. (2007) Structural and dynamical alignment of enzymes with partial structural similarity J. Phys.: Condens. Matter 19, 285206
73. Tiana, G., Simona, F., De Mori, G. M. S., Broglia, R. A., and Colombo, G. (2004) Understanding the determinants of stability and folding of small globular proteins from their energetics Protein Sci. 13, 113-124
74. Colacino, S., Tiana, G., and Colombo, G. (2006) Similar folds with different stabilization mechanisms: The cases of Prion and Doppel proteins BMC Struct. Biol. 6, 17
75. Ragona, L., Colombo, G., Catalano, M., and Molinari, H. (2005) Determinants of protein stability and folding: Comparative analysis of β-lactoglobulins and liver basic fatty acid binding protein Proteins 61, 366-376
76. Morra, G. and Colombo, G. (2008) Relationship between energy distribution and fold stability: Insights from molecular dynamics simulations of native and mutant proteins Proteins 72, 660-672
77. Sharp, K. A. and Honig, B. (1990) Electrostatic interactions in macromolecules: Theory and applications Annu. Rev. Biophys. Biophys. Chem. 19, 301-332
78. Davis, M. E. and McCammon, J. A. (1990) Electrostatics in biomolecular structure and dynamics Chem. Rev. 90, 509-521
79. Daura, X., Gademann, K., Jaun, B., Seebacj, D., van Gunsteren, W. F., and Mark, A. E. (1999) Peptide Folding: When Simulation Meets Experiment Angew. Chem., Int. Ed. 38, 236-240
80. Scarabelli, G., Morra, G., and Colombo, G. (2010) Predicting Interaction Sites from the Energetics of Isolated Proteins: A New Approach to Epitope Mapping Biophys. J. 98, 1-10
81. Swain, J. F. and Gierasch, L. M. (2006) The changing landscape of protein allostery Curr. Opin. Struct. Biol. 16, 102-108
82. Amadei, A., Linnsen, A. B. M., and Berendsen, H. J. C. (1993) Essential dynamics of proteins Proteins 17, 412-425
83. Van Alten, D. M. F., Amadei, A., Linnsen, A. B. M., Eijsink, V. G. H., Vriend, G., and Berendsen, H. J. C. (1995) The essential dynamics of thermolysin: Confirmation of the hinge-bending motion and comparison of simulations in vacuum and water Proteins 22, 45-54
84. Prabu-Jeyabalan, M., Nalivaika, E. A., Romano, K., and Schiffer, C. A. (2006) Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate J. Virol. 80, 3607-3616
85. Austin, R. H., Beeson, K. W., Eisenstein, L., Frauenfelder, H., and Gunsalus, I. C. (1975) Dynamics of ligand binding to myoglobin Biochemistry 14, 5355-5373
86. Frauenfelder, H., Sligar, S. G., and Wolynes, P. G. (1991) The energy landscapes and motions of proteins Science 254, 1598-1603
87. Frauenfelder, H., McMahon, B. H., and Fenimore, P. W. (2003) Myoglobin: The hydrogen atom of biology and a paradigm of complexity Proc. Natl. Acad. Sci. U.S.A. 100, 8615-8617
88. Henzler-Wildman, K. A., Thai, V., Lei, M., Ott, M., Wolf-Watz, M., Fenn, T., Pozharski, E., Wilson, M. A., Petsko, G. A., Karplus, M., Hübner, C. G., and Kern, D. (2007) Intrinsic motions along an enzymatic reaction trajectory Nature 450, 838-844
89. Wilson, C. C., McKinney, D., Anders, M., MaWhinney, S., Forster, J., Crimi, C., Southwood, S., Sette, A., Chesnut, R., Newman, M. J., and Livingston, B. D. (2003) Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1 J. Immunol. 171, 5611-5623
90. McKinney, D. M., Skvoretz, R., Livingston, B. D., Wilson, C. C., Anders, M., Chesnut, R. W., Sette, A., Essex, M., Novitsky, V., and Newman, M. J. (2004) Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL J. Immunol. 173, 1941-1950
91. Wilson, C. C., Newman, M. J., Livingston, B. D., MaWhinney, S., Forster, J. E., Scott, J., Schooley, T., and Benson, C. A. (2008) Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy Clin. Vaccine Immunol. 15, 986-994
92. Gorse, G. J., Baden, L. R., Wecker, M., Newman, M. J., Ferrari, G., Weinhold, K. J., Livingston, B. D., Villafana, T. L., Li, H., Noonan, E., and Russel, N. D. (2008) Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults Vaccine 26, 215-223